TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12943623

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy alone (Group A, n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Postoperative radio/chemotherapy (Group B, n=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Postoperative radio/chemotherapy (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy alone (Group A)
Number of subjects: 45
Study: 11056245

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8856711

Group type: EXPERIMENTAL
Intervention: Passive listening condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active attending condition
Number of subjects: 0
Study: 1519838

Group type: EXPERIMENTAL
Intervention: Sulfuric acid (H2SO4) aerosol exposure at 1,000 micrograms/m3
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) control
Number of subjects: 12
Study: 6376299

Group type: EXPERIMENTAL
Intervention: Benzopyrone drug (verum group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 29552975

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 500
Study: 29133522

Group type: EXPERIMENTAL
Intervention: Intensive treatment group in SPRINT
Number of subjects: 13502

Group type: COMPARATOR
Intervention: Standard treatment group in SPRINT
Number of subjects: 13502

Group type: EXPERIMENTAL
Intervention: Intensive treatment group in ACCORD
Number of subjects: 13502

Group type: COMPARATOR
Intervention: Standard treatment group in ACCORD
Number of subjects: 13502

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in SPRINT
Number of subjects: 13502

Group type: COMPARATOR
Intervention: Visit-to-visit variability in ACCORD
Number of subjects: 13502
Study: 26366789

Group type: EXPERIMENTAL
Intervention: Continuous levobupivacaine infiltration at 6.25mg/h for 48h
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (multimodal systemic analgesia without levobupivacaine)
Number of subjects: 68
Study: 23436264

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (8 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (6 mg/kg)
Number of subjects: 0
Study: 20578162

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 105
Study: 18247163

Group type: EXPERIMENTAL
Intervention: CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone)
Number of subjects: 217

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: CMED
Number of subjects: 217

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 217
Study: 16340190

Group type: EXPERIMENTAL
Intervention: Azithromycin (4.5 g total dose, 1 x 500 mg weekly for 3 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d. for 21 days)
Number of subjects: 63
Study: 12775138

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fexofenadine 180 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10707787

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous unpurged stem-cell transplantation (U)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous purged stem-cell transplantation (P)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Chemotherapy control group (C)
Number of subjects: 89
Study: 9392696

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 761

Group type: COMPARATOR
Intervention: Continuous lumbar epidural analgesia
Number of subjects: 761
Study: 1563815

Group type: EXPERIMENTAL
Intervention: Bioluminescence assay
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Dip sticks for nitrite
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Dip sticks for leucocyte esterase
Number of subjects: 1000
Study: 6365007

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30829023

Group type: EXPERIMENTAL
Intervention: Verteporfin-photodynamic therapy (standard and low-dose/low-fluence protocols)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factors
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Glucocorticoid antagonists
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser with varying parameters
Number of subjects: 3
Study: 29236934

Group type: EXPERIMENTAL
Intervention: Sensory-motor training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 64
Study: 27000785

Group type: EXPERIMENTAL
Intervention: Peer Navigation (PN)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cardiac Surgery Unit
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: General Cardiology Unit
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Interventional Unit
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Closer to Home Referral
Number of subjects: 94
Study: 24505293

Group type: EXPERIMENTAL
Intervention: Baseline presence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific sequence of alternating correct and incorrect answers
Number of subjects: 0
Study: 22932122

Group type: EXPERIMENTAL
Intervention: Lixivaptan (25-100 mg per day, titrated based on daily serum sodium measurements)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Lixivaptan
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 20178572

Group type: EXPERIMENTAL
Intervention: Joint crisis plan (JCP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study: 18214021

Group type: EXPERIMENTAL
Intervention: High-iron rice (3.21 mg/kg Fe)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control rice (0.57 mg/kg Fe)
Number of subjects: 114
Study: 15805364

Group type: EXPERIMENTAL
Intervention: Structured psychological intervention in the first days after birth
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no psychological intervention, counseling available by hospital minister)
Number of subjects: 50
Study: 11980120

Group type: EXPERIMENTAL
Intervention: Drugs and laser radiation (study group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Drugs only (control group)
Number of subjects: 142
Study: 9861118

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine injected at 0.02 ml s‐1 (group slow, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine injected at 0.25 ml s‐1 (group fast, n = 30)
Number of subjects: 60
Study: 7896945

Group type: EXPERIMENTAL
Intervention: Hyposensitization procedure (UVB treatment and subcutaneous nickel sulfate administration)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (UVB treatment only)
Number of subjects: 21
Study: 2631476

Group type: EXPERIMENTAL
Intervention: 2 mg gallopamil (G)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.1 mg/kg propranolol (P)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.12 mg/kg Atenolol (A)
Number of subjects: 32
Study: 320919

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol (800 g daily for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 33
Study: 31093613

Group type: EXPERIMENTAL
Intervention: SmartMouth Clinical DDS (SM)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 76
Study: 27029938

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (home based exercise five days/week and progressive resistance training two days/week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (home based exercise seven days/week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both groups (Progressive resistance training and Control)
Number of subjects: 55
Study: 26021829

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor (gemigliptin)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 23892704

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300 U
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 21889413

Group type: EXPERIMENTAL
Intervention: WebEase (Epilepsy Awareness, Support, and Education)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Completion of WebEase modules
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: WebEase program
Number of subjects: 148

Group type: COMPARATOR
Intervention: Waitlist control group (WCL)
Number of subjects: 148
Study: 19438408

Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 165

Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 165
Study: 17720067

Group type: EXPERIMENTAL
Intervention: Nevanac (nepafenac 0.1%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acular LS (ketorolac 0.4%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Xibrom (bromfenac 0.09%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Amfenac
Number of subjects: 75
Study: 16208048

Group type: EXPERIMENTAL
Intervention: Coconut oil massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineral oil massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (powder) massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurobehavioral assessment
Number of subjects: 0
Study: 11860048

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Traditional measures of nicotine dependence
Number of subjects: 505
Study: 9486387

Group type: EXPERIMENTAL
Intervention: Two doses of Hib vaccine
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Three doses of Hib vaccine
Number of subjects: 111
Study: 8106775

Group type: EXPERIMENTAL
Intervention: Cold-adapted reassortant influenza B/Ann Arbor/1/86 or B/Yamagata/16/88 viruses (10(7.2) TCID50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral trivalent inactivated influenza vaccine containing either influenza B/Ann Arbor/86 or B/Yamagata/88 hemagglutinin antigens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2633018

Group type: EXPERIMENTAL
Intervention: Heavy bupivacaine 12 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tetracaine 12 mg in 2.5 mL of 10% dextrose
Number of subjects: 43
Study: 56898

Group type: EXPERIMENTAL
Intervention: 2.5% Oxypolygelatine-solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4.5% Dextran 60 solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch solution
Number of subjects: 30
Study: 31707618

Group type: EXPERIMENTAL
Intervention: System B unit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Elements Obturation Unit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: B&L SuperEndo Alpha II unit
Number of subjects: 45
Study: 30644627

Group type: EXPERIMENTAL
Intervention: Vaping reinforcement (indexed by vaping frequency, e-cigarette characteristics)
Number of subjects: 2896

Group type: EXPERIMENTAL
Intervention: Vaping enthusiasm (measured by e-cigarette modifications, using non-tobacco flavors, puffs per use)
Number of subjects: 2896

Group type: EXPERIMENTAL
Intervention: Nicotine/tobacco flavor (nicotine strength, tobacco flavors)
Number of subjects: 2896
Study: 29173739

Group type: EXPERIMENTAL
Intervention: 2-week psychosocial intervention targeting psychosocial factors
Number of subjects: 310

Group type: COMPARATOR
Intervention: Health promotion control
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 2-week psychosocial intervention
Number of subjects: 310
Study: 26009916

Group type: EXPERIMENTAL
Intervention: Immediate placement of a provisional crown after sinus elevation bone grafting at the time of implant placement (G2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Immediate placement of a provisional crown with no bone augmentation (G3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Delayed restoration after sinus elevation bone grafting followed by a 6-month healing period (G4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: G2 vs G3
Number of subjects: 80

Group type: COMPARATOR
Intervention: G2 vs G4
Number of subjects: 80

Group type: COMPARATOR
Intervention: G3 vs G4
Number of subjects: 80
Study: 23208767

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional hand‐tied ligation (CT)
Number of subjects: 59
Study: 21615360

Group type: EXPERIMENTAL
Intervention: Surgical resection of the ilioinguinal nerve
Number of subjects: 19

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Surgical resection after medical treatment
Number of subjects: 19
Study: 19651921

Group type: EXPERIMENTAL
Intervention: Combination treatment (perindopril-indapamide + intensive glucose control)
Number of subjects: 11140
Study: 16337687

Group type: EXPERIMENTAL
Intervention: Morning light treatment for 8 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Baseline SIGH‐SAD ratings
Number of subjects: 43

Group type: COMPARATOR
Intervention: Posttreatment SIGH‐SAD ratings
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: T(min) estimated pre- and posttreatment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Phase of sleep-wake rhythm assessed by daily sleep logs
Number of subjects: 43
Study: 15349005

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release (VXR)
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 2045
Study: 12807696

Group type: EXPERIMENTAL
Intervention: Asthma nurse specialist intervention (n = 50)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care group (n = 46)
Number of subjects: 96
Study: 9658370

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 100
Study: 8519507

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current recommendations for breast cancer screening (mammography, clinical breast examination, breast self-examination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future randomized trial of mammography in women younger than 50 years
Number of subjects: 0
Study: 2212961

Group type: EXPERIMENTAL
Intervention: ESAT 6660 glucose analyser
Number of subjects: 21
Study: 115049

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 320 microgram/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ethanol 0.54 g/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31734442

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 94
Study: 28129069

Group type: EXPERIMENTAL
Intervention: Risk information presented at the bottom of the homepage
Number of subjects: 5246

Group type: EXPERIMENTAL
Intervention: Risk information presented at the bottom of the homepage with a signal above indicating that the risk information was located below
Number of subjects: 5246

Group type: EXPERIMENTAL
Intervention: Risk information presented on a linked secondary page
Number of subjects: 5246

Group type: EXPERIMENTAL
Intervention: Risk information format varied (paragraph, checklist, bulleted list, highlighted box)
Number of subjects: 5246
Study: 25587056

Group type: EXPERIMENTAL
Intervention: Adaptive optics microperimetry (AOMP) at normal-appearing cones (N) sites
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adaptive optics microperimetry (AOMP) at dimly reflecting cones (D) sites
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adaptive optics microperimetry (AOMP) at RPE cell mosaics (R) sites
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Overall lesion surface area
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Visual sensitivity assessment
Number of subjects: 3
Study: 23827726

Group type: EXPERIMENTAL
Intervention: AZD1981 1000 mg twice daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 21691611

Group type: EXPERIMENTAL
Intervention: Titanium oxide-anodized (ADZ) implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 10
Study: 19782872

Group type: EXPERIMENTAL
Intervention: Drain inserted into the subdural space
Number of subjects: 269

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 269
Study: 16905387

Group type: EXPERIMENTAL
Intervention: Screen-detected invasive cancers
Number of subjects: 232

Group type: COMPARATOR
Intervention: Previous mammograms of women with screen-detected cancer
Number of subjects: 232
Study: 15526717

Group type: EXPERIMENTAL
Intervention: Serum leptin levels in girls with premature pubarche (PP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Serum leptin levels in prepubertal controls (C)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum DHEAS levels in girls with premature pubarche (PP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Serum DHEAS levels in prepubertal controls (C)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum androstenedione (A) levels in girls with premature pubarche (PP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Serum androstenedione (A) levels in prepubertal controls (C)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum insulin (I) levels in girls with obesity (OB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Serum insulin (I) levels in non-obese (nOB) girls
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fasting glucose (G) levels in girls with obesity (OB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fasting glucose (G) levels in non-obese (nOB) girls
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Total cholesterol (TC) levels in girls with obesity (OB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Total cholesterol (TC) levels in non-obese (nOB) girls
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) observed in girls with obesity (OB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Insulin resistance (IR) observed in non-obese (nOB) girls
Number of subjects: 39
Study: 11251136

Group type: EXPERIMENTAL
Intervention: 30 mL of 0.25% bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 9210503

Group type: EXPERIMENTAL
Intervention: BT563 (10 mg/day; days 0-12; n=39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ATG (5 mg/kg/day; days 0-6; n=41)
Number of subjects: 80
Study: 7962884

Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP) program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Associative Therapy (AT; attention-control program)
Number of subjects: 18
Study: 29533726

Group type: EXPERIMENTAL
Intervention: Cold water immersion with menthol (CMWI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cold water immersion without menthol (CWI)
Number of subjects: 8
Study: 26420062

Group type: EXPERIMENTAL
Intervention: Stepped care (n = 47)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Care as usual (n = 48)
Number of subjects: 95
Study: 25229735

Group type: EXPERIMENTAL
Intervention: FES-assisted walking therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic and resistance training program (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (FES and control)
Number of subjects: 0
Study: 22739979

Group type: EXPERIMENTAL
Intervention: Intensive nurse practitioner support
Number of subjects: 788

Group type: COMPARATOR
Intervention: Nephrologist care (Control)
Number of subjects: 788
Study: 19642883

Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18470300

Group type: EXPERIMENTAL
Intervention: Community intervention to reduce pesticide exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control community
Number of subjects: 0
Study: 15719189

Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 37

Group type: COMPARATOR
Intervention: Handsewn anastomosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 12845933

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 9) performing a progressive cardiovascular graded exercise protocol and resistance training twice a week for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-exercising control group (n = 8)
Number of subjects: 17
Study: 10949062

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rhGH) administered at doses 10-20 times higher than those used for replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parenteral or enteral nutritional formulas
Number of subjects: 0
Study: 9265606

Group type: EXPERIMENTAL
Intervention: Activity programmes for caregivers and changed ward policies to encourage caregiver participation in study wards.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Quality assurance programmes and primary nursing introduced in study wards.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 97
Study: 1412678

Group type: EXPERIMENTAL
Intervention: 37°C incubated apheresis platelets
Number of subjects: 14

Group type: COMPARATOR
Intervention: Paired control platelets
Number of subjects: 14
Study: 6483639

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Phenyltoloxamine 60 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen 650 mg and phenyltoloxamine 60 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 31364490

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 15526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study: 29947090

Group type: EXPERIMENTAL
Intervention: Kidneys from donors dying after ligature asphyxiation (both DBD and DCD)
Number of subjects: 409